OrganiGram Aktie

Organigram shareholders voted 93% in favor of acquiring the remaining interests in the Sanity Group and of issuing up to 96,287,602 common shares to Sanity shareholders and BAT subsidiary BT DE Investments. The takeover combines Organigram’s Canadian operations with Sanity’s presence in the German medical cannabis market; Sanity generated a positive EBITDA in 2025. The transaction includes a private placement with BT DE Investments and senior secured credit facilities from ATB Financial and is expected to close in April 2026 after customary conditions are met. » Więcej na de.investing.com

Organigram Global reported for the quarter ended September 30, 2025, earnings of -0.28 CAD per share, after -0.05 CAD in the prior-year quarter. Revenue rose 79.11 percent to 80.1 million CAD. For the fiscal year, EPS was -0.19 CAD on revenue of 259.18 million CAD; analysts had expected EPS of 0.08 CAD and revenue of 251.95 million CAD. » Więcej na finanzen.net

OrganiGram reported Q3 2025 net revenue growth of 72% to $70.8 million and a record gross revenue of $110.2 million, while international revenue rose 208%. The stock fell about 3.77% in premarket trading despite an improved adjusted EBITDA margin and the target to lift gross margin to 40% by the second half of fiscal 2026. Management emphasized a focus on international expansion, operational efficiency and a planned positive free cash flow for FY2026. » Więcej na de.investing.com